161 related articles for article (PubMed ID: 15141336)
41. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.
Venkateswarlu K; Taylor M; Manning NJ; Rinaldi MG; Kelly SL
Antimicrob Agents Chemother; 1997 Apr; 41(4):748-51. PubMed ID: 9087482
[TBL] [Abstract][Full Text] [Related]
42. In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
Illnait-Zaragozi MT; Martínez GF; Curfs-Breuker I; Fernández CM; Boekhout T; Meis JF
Antimicrob Agents Chemother; 2008 Apr; 52(4):1580-2. PubMed ID: 18212095
[TBL] [Abstract][Full Text] [Related]
43. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
44. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
[TBL] [Abstract][Full Text] [Related]
45. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
[TBL] [Abstract][Full Text] [Related]
46. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
47. [In vitro activity of voriconazole against yeast and algae isolates according to new resistance pattern cut-off points].
Pemán J; Cantón E; Calabuig E; Bosch M; Valentí A; Viudes A; Gobernado M
Rev Esp Quimioter; 2006 Mar; 19(1):21-33. PubMed ID: 16688288
[TBL] [Abstract][Full Text] [Related]
48. In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiânia, Brazil.
de F L Fernandes O; Passos XS; Souza LK; Miranda AT; Cerqueira CH; Silva Mdo R
Mem Inst Oswaldo Cruz; 2003 Sep; 98(6):839-41. PubMed ID: 14595465
[TBL] [Abstract][Full Text] [Related]
49. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.
Chen YC; Chang SC; Shih CC; Hung CC; Luhbd KT; Pan YS; Hsieh WC
Diagn Microbiol Infect Dis; 2000 Mar; 36(3):175-83. PubMed ID: 10729660
[TBL] [Abstract][Full Text] [Related]
50. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques.
Moraes EM; Prímola NS; Hamdan JS
Mycoses; 2003 Jun; 46(5-6):164-8. PubMed ID: 12801356
[TBL] [Abstract][Full Text] [Related]
51. [Behaviour azole fungicide and fluconazole in Cryptococcus neoformans clinical and environmental isolates].
Drummond ED; Reimão JQ; Dias AL; de Siqueira AM
Rev Soc Bras Med Trop; 2007; 40(2):209-11. PubMed ID: 17568890
[TBL] [Abstract][Full Text] [Related]
52. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage.
Currie B; Sanati H; Ibrahim AS; Edwards JE; Casadevall A; Ghannoum MA
Antimicrob Agents Chemother; 1995 Sep; 39(9):1934-7. PubMed ID: 8540694
[TBL] [Abstract][Full Text] [Related]
53. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.
Yamazumi T; Pfaller MA; Messer SA; Houston A; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2000 Oct; 44(10):2883-6. PubMed ID: 10991880
[TBL] [Abstract][Full Text] [Related]
54. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
55. Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.
Yamazumi T; Pfaller MA; Messer SA; Houston AK; Boyken L; Hollis RJ; Furuta I; Jones RN
J Clin Microbiol; 2003 Jan; 41(1):267-72. PubMed ID: 12517859
[TBL] [Abstract][Full Text] [Related]
56. Effects of melanin upon susceptibility of Cryptococcus to antifungals.
Ikeda R; Sugita T; Jacobson ES; Shinoda T
Microbiol Immunol; 2003; 47(4):271-7. PubMed ID: 12801064
[TBL] [Abstract][Full Text] [Related]
57. Enhanced activity of antifungal drugs by lysozyme against Cryptococcus neoformans.
Nakamura Y; Kano R; Watanabe S; Takahashi H; Hasegawa A
Mycoses; 1998; 41(5-6):199-202. PubMed ID: 9715633
[TBL] [Abstract][Full Text] [Related]
58. Effect of media on growth rate and susceptibility testing of Cryptococcus neoformans.
St-Germain G; Dion C
Mycoses; 1996; 39(5-6):201-6. PubMed ID: 8909030
[TBL] [Abstract][Full Text] [Related]
59. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
[TBL] [Abstract][Full Text] [Related]
60. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.
Cuenca-Estrella M; Ruiz-Díez B; Martínez-Suárez JV; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 1999 Jan; 43(1):149-51. PubMed ID: 10381115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
